The principle of nuclear medicine is the study of in vivo distribution (in the patient’s body) of specific targets or biological processes for diagnostic and therapeutic purposes. This is achieved using specific markers bound to a radioactive isotope, which is tracked through imaging.
The department applies two imaging techniques: scintigraphy and PET (positron emission tomography).
In 2023, the department focused on innovations in technical and pharmaceutical progress. In particular, new tracers were introduced for the diagnosis and treatment of prostate cancer and Alzheimer’s disease.
Head of Department: Dr. Marc Berto.
Main areas:
- Diagnostics
- PET-CT (18F-FDG) – for oncology, neurology, cardiology
- SPECT/CT – myocardial perfusion, kidney function, bone metastases
- Scintigraphy of thyroid, liver, lungs
- Therapy
- 177Lu-PSMA – treatment of metastatic prostate cancer
- Iodine-131 – therapy for thyroid cancer and hyperthyroidism
- Strontium-89/Samarium-153 – palliative treatment of bone metastases
Unique equipment:
- PET-CT “GE Discovery IQ” – high-sensitivity detector for early tumor diagnosis
- SPECT/CT “GE Infinia Hawkeye 4” – combined functional and anatomical imaging
- Cyclotron – production of radiopharmaceuticals (e.g., 18F-FDG)